title: [Consensus statement on metabolic disorders and cardiovascular risks in patients with human immunodeficiency virus].
abstract: OBJECTIVE
  This consensus document is an update of metabolic disorders and cardiovascular risk (CVR) guidelines for HIV-infected patients.
  
  
  METHODS
  This document has been approved by an expert panel of GEAM, SPNS and GESIDA after reviewing the results of efficacy and safety of clinical trials, cohort and pharmacokinetic studies published in biomedical journals (PubMed and Embase) or presented in medical scientific meetings. Recommendation strength and the evidence in which they are supported are based on the GRADE system.
  
  
  RESULTS
  A healthy lifestyle is recommended, no smoking and at least 30min of aerobic exercise daily. In diabetic patients the same treatment as non-HIV infected patients is recommended. HIV patients with dyslipidemia should be considered as high CVR, thus its therapeutic objective is an LDL less than 100mg/dL. The antihypertensive of ACE inhibitors and ARAII families are better tolerated and have a lower risk of interactions. In HIV-patients with diabetes or metabolic syndrome and elevated transaminases with no defined etiology, the recommended is to rule out a hepatic steatosis Recommendations for action in hormone alterations are also updated.
  
  
  CONCLUSIONS
  These new guidelines update previous recommendations regarding all those metabolic disorders involved in CVR. Hormone changes and their management and the impact of metabolic disorders on the liver are also included.
authors.forename: Rosa
authors.initials: R
authors.lastname: Polo Rodríguez
authors.forename: María José
authors.initials: MJ
authors.lastname: Galindo Puerto
authors.forename: Carlos
authors.initials: C
authors.lastname: Dueñas
authors.forename: Carmen
authors.initials: C
authors.lastname: Gómez Candela
authors.forename: Vicente
authors.initials: V
authors.lastname: Estrada
authors.forename: Noemí G P
authors.initials: NG
authors.lastname: Villar
authors.forename: Jaime
authors.initials: J
authors.lastname: Locutura
authors.forename: Ana
authors.initials: A
authors.lastname: Mariño
authors.forename: Javier
authors.initials: J
authors.lastname: Pascua
authors.forename: Rosario
authors.initials: R
authors.lastname: Palacios
authors.forename: Miguel Ángel
authors.initials: MÁ
authors.lastname: von Wichmman
authors.forename: Julia
authors.initials: J
authors.lastname: Álvarez
authors.forename: Victor
authors.initials: V
authors.lastname: Asensi
authors.forename: José
authors.initials: J
authors.lastname: Lopez Aldeguer
authors.forename: Fernando
authors.initials: F
authors.lastname: Lozano
authors.forename: Eugenia
authors.initials: E
authors.lastname: Negredo
authors.forename: Enrique
authors.initials: E
authors.lastname: Ortega
authors.forename: Enric
authors.initials: E
authors.lastname: Pedrol
authors.forename: Félix
authors.initials: F
authors.lastname: Gutiérrez
authors.forename: Jesús
authors.initials: J
authors.lastname: Sanz Sanz
authors.forename: Esteban
authors.initials: E
authors.lastname: Martínez Chamorro
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects; D002318:Cardiovascular Diseases / Q000453:epidemiology* / Q000517:prevention & control; D015897:Comorbidity; D015444:Exercise; D015658:HIV Infections / Q000453:epidemiology*; D006293:Health Promotion; D000070497:Healthy Lifestyle; D006801:Humans; D052439:Lipid Metabolism Disorders / Q000139:chemically induced / Q000453:epidemiology; D008659:Metabolic Diseases / Q000139:chemically induced / Q000453:epidemiology* / Q000628:therapy; D012307:Risk Factors; D012735:Sexual Dysfunction, Physiological / Q000453:epidemiology / Q000209:etiology; D016540:Smoking Cessation
chemical_list: D019380:Anti-HIV Agents
keywords: Alteraciones metabólicas; Cardiovascular risk; Human immunodeficiency virus infection; Infección por el virus de la inmunodeficiencia humana; Metabolic disorders; Riesgo cardiovascular